Citing the lack of evidence that they work for the indication, the European Medicines Agency's advisory group CHMP has withdrawn its authorization for the use of omega-3 fatty acid medications to prevent further heart and blood vessel problems in heart attack patients. The meds have been approved in the EU since 2000 at a dose of 1g/day for this indication.
The medications remain approved for reducing triglyceride levels.
Now read: Amarin Corp.: A Valuation »
Subscribe for full text news in your inbox